Product Images Pazopanib
View Photos of Packaging, Labels & Appearance
Product Label Images
The following 4 images provide visual information about the product associated with Pazopanib NDC 42291-939 by Avkare, such as packaging, labeling, and the appearance of the drug itself. This resource could be helpful for medical professionals, pharmacists, and patients seeking to verify medication information and ensure they have the correct product.
120 - 939 12
new - pazopanib tablets 200 mg a217517 1
1 - pazopanib tablets 200 mg a217517 2
22 - pazopanib tablets 200 mg a217517 3
This data indicates the results of a study comparing the progression-free survival of patients treated with Pazopanib versus a placebo. The median progression-free survival was 4.6 months for Pazopanib (N=246) compared to 1.6 months for the placebo group (N=123). The hazard ratio was calculated as 0.35 with a 95% confidence interval from 0.26 to 0.48, and the p-value was less than 0.001. This suggests that patients treated with Pazopanib had a significantly longer progression-free survival compared to those on placebo.*
* The product label images have been analyzed using a combination of traditional computing and machine learning techniques. It should be noted that the descriptions provided may not be entirely accurate as they are experimental in nature. Use the information in this page at your own discretion and risk.
